Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Desensitization to biological agents used in rheumatology.
Reumatologia
February 2020
Department of Rheumatology, Medical University of Lodz, Poland.
Biological agents such as monoclonal antibodies and fusion proteins are widely used for the treatment of patients with various rheumatic disorders, influencing the quality of life, disability and even mortality in patients. However, biological agents can evoke adverse reactions of different grades of severity. Although drug avoidance remains a gold standard in the care of patients hypersensitive to medication, in certain clinical situations the culprit drug is the drug of choice and cannot be replaced by another equally effective compound.
View Article and Find Full Text PDFRapid Desensitization to Adalimumab Is Associated With Decreased Basophil Sensitivity.
J Investig Allergol Clin Immunol
April 2019
CHU de Clermont-Ferrand, Service d'Immunologie Biologique, Pôle de Biologie et d'anatomopathologie, Clermont-Ferrand, France.
Subcutaneous Injectable Drugs Hypersensitivity and Desensitization: Insulin and Monoclonal Antibodies.
Immunol Allergy Clin North Am
November 2017
Division of Allergy and Immunology, The University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390, USA.
Injectable drugs, including monoclonal antibodies, are becoming crucial components in the management of chronic diseases. The most common side effects are local reactions at the site of administration. With the increased and prolonged use of these medications, we are seeing increased reports of hypersensitivity reactions.
View Article and Find Full Text PDFDesensitization to Adalimumab: An Example of Repeated Desensitization to a Biological Agent.
Drug Saf Case Rep
December 2015
Division of Immunology and Allergic Diseases, Department of Internal Medicine, Gulhane Military Medical Academy and Medical School, Etlik, 06018, Ankara, Turkey.
Biological agents seem to have been more effective than classic immunosuppressive drugs; however, the adverse events including the hypersensitivity reactions are the main drawbacks of these drugs. We report a 35-year-old man who was treated with adalimumab for ankylosing spondylitis, had a local reaction on the injection site, and generalized itching with rash at the 62nd dose and repeated desensitizations to him with adalimumab. One month after the reaction, skin prick test was performed with a commercial preparation of adalimumab.
View Article and Find Full Text PDFIgE antibodies and skin tests in immediate hypersensitivity reactions to infliximab in inflammatory bowel disease: impact on infliximab retreatment.
Eur J Gastroenterol Hepatol
October 2015
aDepartment of Dermatology and Allergy bInserm U954, Department of Hepato-Gastroenterology cInserm U954, Department of Pediatrics dInserm U-954, NGERE - Nutrition, Genetics, and Environmental Risk Exposure, Faculty of Medicine, University Hospital of Nancy, Lorraine University, Vandoeuvre les Nancy, France.
Background: Infliximab (IFX) is used for the treatment of inflammatory bowel diseases (IBD). Immediate hypersensitivity reactions (HR) to IFX are frequently reported.
Objectives: We investigated immunoglobulin E (IgE)-mediated mechanisms underlying immediate HR to IFX.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!